Advanced Search >

Risk Minimisation Materials

Cablivi 10 mg powder and solvent for solution for injection- Healthcare Professional Letter- Risk Minimisation Information for Healthcare Professionals

Sanofi Genzyme is required to distribute copies of the approved risk minimisation educational material for Cablivi ® (caplacizumab) to relevant healthcare professionals. Caplacizumab, the active ingredient of Cablivi, is a humanised bivalent Nanobody targeting the A1 domain of von Willebrand factor. For hard copies please contact our medical information department at 0845 372 7101 or email [email protected]

For Healthcare Professionals

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue